赛诺菲进军“互联网+慢病管理” 共拓互联网医院新生态,助力实现“健康中国2030”

2020-09-25 Forest 网络

赛诺菲中国与京东健康联合宣布,赛诺菲正式成为京东健康糖尿病中心(下简称“中心”)的首家深度合作伙伴,共同打造基于互联网医院的慢病管理新模式。

pixbay

9月22日,赛诺菲中国与京东健康联合宣布,赛诺菲正式成为京东健康糖尿病中心(下简称“中心”)的首家深度合作伙伴,共同打造基于互联网医院的慢病管理新模式。赛诺菲始终以患者为中心,积极探索互联网医院业务创新模式,为患者提供从问诊、处方、送药到家、健康管理等“一站式”服务。赛诺菲中国商务与多元化事业部总经理夏春表示,“赛诺菲将以糖尿病为起点,依托自身在慢病领域100多年的诊疗经验,与互联网医院合作伙伴共同开拓新生态,助力实现‘健康中国2030’。”

我国慢病死亡人数占比高达88% 疾病负担占比超过70%

根据国家卫生健康委在“健康中国行动”之防控重大疾病各专项行动新闻发布会上公布的数据,慢性非传染性疾病已经成为我国居民主要死亡原因和疾病负担,目前我国心脑血管疾病、癌症、慢性呼吸系统疾病、糖尿病等慢性非传染性疾病死亡人数占总死亡人数的88%,导致的疾病负担占总疾病负担的70%以上,是普遍影响我国居民健康的主要疾病,成为制约健康预期寿命提高的重要因素。

“互联网+慢病管理”成为中国慢病管理发展的大势所趋

年初爆发的新冠疫情让广大慢病患者陷入“就诊难、开药难”的困境。彼时,互联网医院跨越地域和时间的限制,让患者“有医可问”、“有处方可开”、“有药可吃”。同时,在国家出台的“三大互联网管理办法”[ 《互联网诊疗管理办法(试行)》、《互联网医院管理办法(试行)》和《远程医疗服务管理规范(试行)》]的加持下,互联网医院进入发展的快车道——在线复诊、网络购药、病情回访等多个环节的便利,被越来越多的慢病患者所接受。据《2020年中国互联网+医疗行业研究报告》显示,41.6%的受访者在有慢病管理需求时,更倾向于应用线上医疗。解决当今中国慢病管理的痛点,更好地满足广大慢病患者的健康诉求,成为互联网医院助力实现健康中国2030的重要使命。

 赛诺菲正式进军“互联网+慢病管理” 共拓互联网医院新生态 助力实现“健康中国2030”

基于这一初心,领先跨国药企赛诺菲在2019年5月就组建了业界首创的专注于互联网医院的团队,此次与京东健康合作,标志着赛诺菲以糖尿病为切入点,正式开始“互联网+慢病管理”的征程。患者可以随时随地通过互联网医院享受“诊前、诊中、诊后”一站式服务,包括诊前咨询(互联网问询导诊),诊中便捷沟通,增强医患信任,诊后治疗管理(包括续方、复诊、患者教育、送药上门等)。通过互联网医院平台,提高医疗可及性。

京东健康慢病医疗部总经理熊荣华表示:“京东健康糖尿病中心始终坚持以公众健康和患者利益为中心,不断丰富和完善专病健康管理服务,从而推动糖尿病预防与诊疗一体化发展,探索符合中国国情的软件+硬件、院内+院外、线上+线下一体化的慢病防控模式和道路,并尝试将人工智能、大数据等技术应用在医疗服务的各个环节。我们很高兴此次能与赛诺菲合作,共同探索如何利用互联网医院的技术优势,解决糖尿病管理领域的痛点。”

未来,赛诺菲中国将携手更多合作伙伴,不断探索基于互联网的慢病管理创新解决方案,共同构建更完善的慢病管理体系,服务中国更多慢病患者的需求,助力国家实现“健康中国2030”。

 

参考资料:

 《健康中国行动推进委员会办公室2019年7月31日新闻发布会文字实录》http://www.nhc.gov.cn/xcs/s7847/201907/0d95adec49f84810a6d45a0a1e997d67.shtml 

 《互联网诊疗管理办法(试行)》、《互联网医院管理办法(试行)》和《远程医疗服务管理规范(试行)》

 《2020年中国互联网+医疗行业研究报告》

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1924353, encodeId=7a2c192435306, content=<a href='/topic/show?id=8e09585440c' target=_blank style='color:#2F92EE;'>#新生态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58544, encryptionId=8e09585440c, topicName=新生态)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Wed Sep 30 16:27:24 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944036, encodeId=327d19440362d, content=<a href='/topic/show?id=c06a2e71465' target=_blank style='color:#2F92EE;'>#健康中国2030#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27714, encryptionId=c06a2e71465, topicName=健康中国2030)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Sun Aug 22 00:27:24 CST 2021, time=2021-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274336, encodeId=794012e433600, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Sun Sep 27 02:27:24 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438104, encodeId=2c931438104a9, content=<a href='/topic/show?id=e08c2412394' target=_blank style='color:#2F92EE;'>#互联网+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24123, encryptionId=e08c2412394, topicName=互联网+)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sun Sep 27 02:27:24 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888224, encodeId=8b7b8882249b, content=<a href='/topic/show?id=88b82413875' target=_blank style='color:#2F92EE;'>#互联网医疗#</a>是未来, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24138, encryptionId=88b82413875, topicName=互联网医疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Fri Sep 25 11:33:56 CST 2020, time=2020-09-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1924353, encodeId=7a2c192435306, content=<a href='/topic/show?id=8e09585440c' target=_blank style='color:#2F92EE;'>#新生态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58544, encryptionId=8e09585440c, topicName=新生态)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Wed Sep 30 16:27:24 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944036, encodeId=327d19440362d, content=<a href='/topic/show?id=c06a2e71465' target=_blank style='color:#2F92EE;'>#健康中国2030#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27714, encryptionId=c06a2e71465, topicName=健康中国2030)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Sun Aug 22 00:27:24 CST 2021, time=2021-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274336, encodeId=794012e433600, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Sun Sep 27 02:27:24 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438104, encodeId=2c931438104a9, content=<a href='/topic/show?id=e08c2412394' target=_blank style='color:#2F92EE;'>#互联网+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24123, encryptionId=e08c2412394, topicName=互联网+)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sun Sep 27 02:27:24 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888224, encodeId=8b7b8882249b, content=<a href='/topic/show?id=88b82413875' target=_blank style='color:#2F92EE;'>#互联网医疗#</a>是未来, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24138, encryptionId=88b82413875, topicName=互联网医疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Fri Sep 25 11:33:56 CST 2020, time=2020-09-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1924353, encodeId=7a2c192435306, content=<a href='/topic/show?id=8e09585440c' target=_blank style='color:#2F92EE;'>#新生态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58544, encryptionId=8e09585440c, topicName=新生态)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Wed Sep 30 16:27:24 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944036, encodeId=327d19440362d, content=<a href='/topic/show?id=c06a2e71465' target=_blank style='color:#2F92EE;'>#健康中国2030#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27714, encryptionId=c06a2e71465, topicName=健康中国2030)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Sun Aug 22 00:27:24 CST 2021, time=2021-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274336, encodeId=794012e433600, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Sun Sep 27 02:27:24 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438104, encodeId=2c931438104a9, content=<a href='/topic/show?id=e08c2412394' target=_blank style='color:#2F92EE;'>#互联网+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24123, encryptionId=e08c2412394, topicName=互联网+)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sun Sep 27 02:27:24 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888224, encodeId=8b7b8882249b, content=<a href='/topic/show?id=88b82413875' target=_blank style='color:#2F92EE;'>#互联网医疗#</a>是未来, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24138, encryptionId=88b82413875, topicName=互联网医疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Fri Sep 25 11:33:56 CST 2020, time=2020-09-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1924353, encodeId=7a2c192435306, content=<a href='/topic/show?id=8e09585440c' target=_blank style='color:#2F92EE;'>#新生态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58544, encryptionId=8e09585440c, topicName=新生态)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Wed Sep 30 16:27:24 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944036, encodeId=327d19440362d, content=<a href='/topic/show?id=c06a2e71465' target=_blank style='color:#2F92EE;'>#健康中国2030#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27714, encryptionId=c06a2e71465, topicName=健康中国2030)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Sun Aug 22 00:27:24 CST 2021, time=2021-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274336, encodeId=794012e433600, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Sun Sep 27 02:27:24 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438104, encodeId=2c931438104a9, content=<a href='/topic/show?id=e08c2412394' target=_blank style='color:#2F92EE;'>#互联网+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24123, encryptionId=e08c2412394, topicName=互联网+)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sun Sep 27 02:27:24 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888224, encodeId=8b7b8882249b, content=<a href='/topic/show?id=88b82413875' target=_blank style='color:#2F92EE;'>#互联网医疗#</a>是未来, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24138, encryptionId=88b82413875, topicName=互联网医疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Fri Sep 25 11:33:56 CST 2020, time=2020-09-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1924353, encodeId=7a2c192435306, content=<a href='/topic/show?id=8e09585440c' target=_blank style='color:#2F92EE;'>#新生态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58544, encryptionId=8e09585440c, topicName=新生态)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Wed Sep 30 16:27:24 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944036, encodeId=327d19440362d, content=<a href='/topic/show?id=c06a2e71465' target=_blank style='color:#2F92EE;'>#健康中国2030#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27714, encryptionId=c06a2e71465, topicName=健康中国2030)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Sun Aug 22 00:27:24 CST 2021, time=2021-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274336, encodeId=794012e433600, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Sun Sep 27 02:27:24 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438104, encodeId=2c931438104a9, content=<a href='/topic/show?id=e08c2412394' target=_blank style='color:#2F92EE;'>#互联网+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24123, encryptionId=e08c2412394, topicName=互联网+)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sun Sep 27 02:27:24 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888224, encodeId=8b7b8882249b, content=<a href='/topic/show?id=88b82413875' target=_blank style='color:#2F92EE;'>#互联网医疗#</a>是未来, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24138, encryptionId=88b82413875, topicName=互联网医疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Fri Sep 25 11:33:56 CST 2020, time=2020-09-25, status=1, ipAttribution=)]

相关资讯

赛诺菲的IL-4/IL-13单抗Dupixent,在特应性皮炎儿童患者中显示出明显益处

III期试验结果显示,将Dupixent与临床护理标准局部皮质类固醇(TCS)结合使用,可显著缓解6-11岁严重特应性皮炎患者的疾病症状。

赛诺菲拟招募数千受试者开展新冠疫苗试验,已在多国讨论购买

法国制药商赛诺菲(Sanofi SA)表示,计划在全球范围内招募数千名受试者,用于与英国制药公司葛兰素史克(GlaxoSmithKline Plc)合作开发的新冠病毒疫苗试验。公司还表示,已经与多个国

赛诺菲/GSK启动新冠疫苗I/II期研究

9月3日,赛诺菲/GSK宣布启动佐剂新冠疫苗的I/II期临床试验。该项研究采用随机、双盲、安慰剂对照设计,计划在美国的11个研究中心入组440例健康受试者,主要评估疫苗的安全性、耐受性和免疫原性。

被暂停的牛津-阿斯利康新冠疫苗临床试验将恢复

9月12日, 从牛津大学疫苗研发团队处获悉,该团队与阿斯利康合作研发的新冠疫苗将重新恢复临床试验。牛津大学疫苗团队向澎湃新闻发送邮件称,该款新冠疫苗的随机对照临床试验将在英国所有临床试验地点继续进行。

赛诺菲合并欧洲六大基地创API企业 或将首次公开募股

2月24日,赛诺菲宣布将创建一家生产和销售原料药(API)的公司,以将其在欧洲的六个API生产基地合并在一起。

FDA批准赛诺菲靶向CD38的单抗Sarclisa,用于治疗复发或难治的多发性骨髓瘤

美国食品和药物管理局已批准赛诺菲的Sarclisa(isatuximab-irfc)用于治疗多发性骨髓瘤。该药物靶向骨髓瘤细胞表面的CD38蛋白发挥作用,这是继强生公司的Darzalex(daratumumab)获批之后第二个靶向CD38蛋白的药物。